Department of General Surgery, China-Japan Friendship Hospital, Beijing, 100029, China.
Surg Today. 2024 May;54(5):397-406. doi: 10.1007/s00595-023-02671-3. Epub 2023 Mar 21.
To compare the urinary and sexual outcomes between robot-assisted rectal cancer (RC) surgery (RRCS) and laparoscopic RC surgery (LRCS) using a meta-analysis, searches were conducted of the Embase, PubMed, Cochrane Library, CNKI, and Wanfang databases. The International Prostate Symptom Score (IPSS) was the primary outcome. Eleven studies (790 patients with RRCS and 888 with LRCS) were included. The IPSS scores were significantly lower for RRCS than LRCS from baseline to 3 months (weighted mean difference [WMD] = - 1.21, 95% confidence interval [CI]: - 1.8,-0.62, I = 89.9%), to 6 months (WMD = - 1.13, 95% CI: - 1.74, - 0.52, I = 93.3%), and to 12 months (WMD = - 0.93, 95% CI: - 1.59, - 0.26, I = 93.8%). The International Index of Erectile Function (IIEF) scores were significantly higher for RRCS than LRCS from baseline to 3 months (WMD = 3.36, 95% CI: 1.28, 5.44, I = 92.7%). The female sexual function index (FSFI) scores were significantly higher for RRCS than LRCS from baseline to 3 months (WMD = 1.31, 95% CI: 0.87, 1.76, I = 0), to 6 months (WMD = 2.36, 95% CI: 1.93, 2.79, I = 24.3%), and to 12 months (WMD = 1.67, 95% CI: 0.41, 2.93, I = 90.9%). RRCS also achieved a better recovery of the urological and sexual function than LRCS for patients with RC. Larger-scale prospective randomized control trials are needed to verify these results.
为了通过荟萃分析比较机器人辅助直肠癌(RC)手术(RRCS)和腹腔镜 RC 手术(LRCS)的尿控和性功能结果,检索了 Embase、PubMed、Cochrane 图书馆、中国知网和万方数据库。国际前列腺症状评分(IPSS)是主要结局。纳入了 11 项研究(RRCS 组 790 例,LRCS 组 888 例)。RRCS 在基线至 3 个月(加权均数差 [WMD] = -1.21,95%置信区间 [CI]:-1.8,-0.62,I = 89.9%)、6 个月(WMD = -1.13,95%CI:-1.74,-0.52,I = 93.3%)和 12 个月(WMD = -0.93,95%CI:-1.59,-0.26,I = 93.8%)时的 IPSS 评分明显低于 LRCS。RRCS 在基线至 3 个月(WMD = 3.36,95%CI:1.28,5.44,I = 92.7%)、6 个月(WMD = 2.36,95%CI:1.93,2.79,I = 24.3%)和 12 个月(WMD = 1.67,95%CI:0.41,2.93,I = 90.9%)时的国际勃起功能指数(IIEF)评分明显高于 LRCS。RRCS 在基线至 3 个月(WMD = 1.31,95%CI:0.87,1.76,I = 0)、6 个月(WMD = 2.36,95%CI:1.93,2.79,I = 24.3%)和 12 个月(WMD = 1.67,95%CI:0.41,2.93,I = 90.9%)时的女性性功能指数(FSFI)评分明显高于 LRCS。RRCS 组患者的尿控和性功能恢复也优于 LRCS 组。需要更大规模的前瞻性随机对照试验来验证这些结果。